Bide Pharmatech (SH:688073) Xin Lang Cai Jing·2025-08-28 04:06Group 1 - Bid Pharma's stock price dropped by 5.4% to 59.18 CNY per share, with a trading volume of 51.32 million CNY and a turnover rate of 1.94%, resulting in a total market capitalization of 5.378 billion CNY [1] - The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - Guodu Securities has one fund heavily invested in Bid Pharma, with Guodu Jucheng (011389) holding 7,000 shares, accounting for 3.98% of the fund's net value, ranking as the tenth largest holding [2] - The fund has a total scale of 10.2022 million CNY, with a year-to-date return of 7.5% and a one-year return of 11.33% [2] - Since its inception, the fund has experienced a loss of 46.84% [2] Group 3 - The fund managers of Guodu Jucheng are Liao Xiaodong, Zhang Xiaolei, and Gong Yongjin, with varying tenures and performance records [3] - Liao Xiaodong has a tenure of 5 years and 107 days, with the best fund return of -24.14% and the worst return of -64.86% [3] - Zhang Xiaolei has a tenure of 6 years and 257 days, achieving a best return of 80.09% and a worst return of -23.6% [3] - Gong Yongjin has a tenure of 1 year and 148 days, with a consistent return of 7.03% [3]